Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009 - PubMed (original) (raw)
Multicenter Study
. 2012 May;56(5):2364-70.
doi: 10.1128/AAC.05824-11. Epub 2012 Feb 21.
Carl Urban, Scott J Weissman, James H Jorgensen, James S Lewis 2nd, Glen Hansen, Paul H Edelstein, Ari Robicsek, Timothy Cleary, Javier Adachi, David Paterson, John Quinn, Nancy D Hanson, Brian D Johnston, Connie Clabots, Michael A Kuskowski; AMERECUS Investigators
Collaborators, Affiliations
- PMID: 22354301
- PMCID: PMC3346636
- DOI: 10.1128/AAC.05824-11
Multicenter Study
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009
James R Johnson et al. Antimicrob Agents Chemother. 2012 May.
Abstract
Escherichia coli sequence type ST131 (from phylogenetic group B2), often carrying the extended-spectrum-β-lactamase (ESBL) gene bla(CTX-M-15), is an emerging globally disseminated pathogen that has received comparatively little attention in the United States. Accordingly, a convenience sample of 351 ESBL-producing E. coli isolates from 15 U.S. centers (collected in 2000 to 2009) underwent PCR-based phylotyping and detection of ST131 and bla(CTX-M-15). A total of 200 isolates, comprising 4 groups of 50 isolates each that were (i) bla(CTX-M-15) negative non-ST131, (ii) bla(CTX-M-15) positive non-ST131, (iii) bla(CTX-M-15) negative ST131, or (iv) bla(CTX-M-15) positive ST131, also underwent virulence genotyping, antimicrobial susceptibility testing, and pulsed-field gel electrophoresis (PFGE). Overall, 201 (57%) isolates exhibited bla(CTX-M-15), whereas 165 (47%) were ST131. ST131 accounted for 56% of bla(CTX-M-15)-positive- versus 35% of bla(CTX-M-15)-negative isolates (P < 0.001). Whereas ST131 accounted for 94% of the 175 total group B2 isolates, non-ST131 isolates were phylogenetically distributed by bla(CTX-M-15) status, with groups A (bla(CTX-M-15)-positive isolates) and D (bla(CTX-M-15)-negative isolates) predominating. Both bla(CTX-M-15) and ST131 occurred at all participating centers, were recovered from children and adults, increased significantly in prevalence post-2003, and were associated with molecularly inferred virulence. Compared with non-ST131 isolates, ST131 isolates had higher virulence scores, distinctive virulence profiles, and more-homogeneous PFGE profiles. bla(CTX-M-15) was associated with extensive antimicrobial resistance and ST131 with fluoroquinolone resistance. Thus, E. coli ST131 and bla(CTX-M-15) are emergent, widely distributed, and predominant among ESBL-positive E. coli strains in the United States, among children and adults alike. Enhanced virulence and antimicrobial resistance have likely promoted the epidemiological success of these emerging public health threats.
Figures
Fig 1
Principal coordinate analysis of virulence genotype data (upper panel) and antimicrobial resistance data (lower panel) among 200 Escherichia coli isolates (collected in 2000 to 2009) in relation to ST131 and _bla_CTX-M-15 status. Populations 1 to 4 correspond to the groups shown in the tables (i.e., Table 1, non-ST131 _bla_CTX-M-15 negative; Table 2, non-ST131 _bla_CTX-M-15 positive; Table 3, ST131 _bla_CTX-M-15 negative; Table 4, ST131 _bla_CTX-M-15 positive). Upper panel (virulence genotypes): coordinates 1 and 2 capture 58% and 12% of total variation, respectively. Note the marked separation of (overlapping) populations 1 and 2 from (overlapping) populations 3 and 4. Lower panel (antimicrobial resistance): coordinates 1 and 2 capture 32% and 26% of total variation, respectively. Note the marked overlap of all four populations.
Similar articles
- Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.
Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G, Mora A, Blanco JE, López C, Cortés P, Llagostera M, Leflon-Guibout V, Puentes B, Mamani R, Herrera A, Coira MA, García-Garrote F, Pita JM, Blanco J. Blanco M, et al. J Antimicrob Chemother. 2009 Jun;63(6):1135-41. doi: 10.1093/jac/dkp122. Epub 2009 Apr 7. J Antimicrob Chemother. 2009. PMID: 19351692 - Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.
Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Johnson JR, et al. Clin Infect Dis. 2010 Aug 1;51(3):286-94. doi: 10.1086/653932. Clin Infect Dis. 2010. PMID: 20572763 - Prevalence of CTX-M extended-spectrum beta-lactamases and sequence type 131 in Korean blood, urine, and rectal Escherichia coli isolates.
Graham SE, Zhang L, Ali I, Cho YK, Ismail MD, Carlson HA, Foxman B. Graham SE, et al. Infect Genet Evol. 2016 Jul;41:292-295. doi: 10.1016/j.meegid.2016.04.020. Epub 2016 Apr 19. Infect Genet Evol. 2016. PMID: 27101781 - A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.
Banerjee R, Johnson JR. Banerjee R, et al. Antimicrob Agents Chemother. 2014 Sep;58(9):4997-5004. doi: 10.1128/AAC.02824-14. Epub 2014 May 27. Antimicrob Agents Chemother. 2014. PMID: 24867985 Free PMC article. Review. - Escherichia coli ST131, an intriguing clonal group.
Nicolas-Chanoine MH, Bertrand X, Madec JY. Nicolas-Chanoine MH, et al. Clin Microbiol Rev. 2014 Jul;27(3):543-74. doi: 10.1128/CMR.00125-13. Clin Microbiol Rev. 2014. PMID: 24982321 Free PMC article. Review.
Cited by
- The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics.
Banerjee R, Johnston B, Lohse C, Chattopadhyay S, Tchesnokova V, Sokurenko EV, Johnson JR. Banerjee R, et al. Antimicrob Agents Chemother. 2013 Dec;57(12):5912-7. doi: 10.1128/AAC.01065-13. Epub 2013 Sep 16. Antimicrob Agents Chemother. 2013. PMID: 24041881 Free PMC article. - Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago Region, 2007 to 2010.
Banerjee R, Robicsek A, Kuskowski MA, Porter S, Johnston BD, Sokurenko E, Tchesnokova V, Price LB, Johnson JR. Banerjee R, et al. Antimicrob Agents Chemother. 2013 Dec;57(12):6385-8. doi: 10.1128/AAC.01604-13. Epub 2013 Sep 30. Antimicrob Agents Chemother. 2013. PMID: 24080662 Free PMC article. - Sub-typing of extended-spectrum-β-lactamase-producing isolates from a nosocomial outbreak: application of a 10-loci generic Escherichia coli multi-locus variable number tandem repeat analysis.
Karami N, Helldal L, Welinder-Olsson C, Ahrén C, Moore ER. Karami N, et al. PLoS One. 2013 Dec 31;8(12):e83030. doi: 10.1371/journal.pone.0083030. eCollection 2013. PLoS One. 2013. PMID: 24391735 Free PMC article. - Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype.
Johnson JR, Porter SB, Johnston BD, Thuras P. Johnson JR, et al. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1888-91. doi: 10.1128/AAC.02403-15. Antimicrob Agents Chemother. 2015. PMID: 26666925 Free PMC article.
References
- Clermont O, et al. 2009. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J. Antimicrob. Chemother. 64:274–277 - PubMed
- Clermont O, et al. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother. 61:1024–1028 - PubMed
- Clinical Laboratory Standards Institute 2009. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement (M100-S19). Clinical Laboratory Standards Institute, Wayne, PA
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical